Batf2 Antibodies

Basic leucine zipper transcriptional factor ATF-like 2 (Batf2)

AP-1 family transcription factor that regulates the differentiation of lineage-specific cells from the immune system. Selectively suppresses CYR61/CCN1 transcription and hence blocks the downstream cell proliferation signals produced by CYR61 and inhibits CYR61-induced anchorage-independent growth and invasion in many cancer types.

Maybe acts by interfering with AP-1 binding to CYR61 promoter (By similarity). Following infection, participates in the differentiation of CD8(+) thymic conventional dendritic cells from the immune system.

Gene Information

Mouse
Gene Name:	Batf2
Uniprot:	Q8R1H8
Entrez:	74481

Family

Belongs to:
bZIP family

Alternative Names

basic leucine zipper transcription factor, ATF-like 2; basic leucine zipper transcriptional factor ATF-like 2; B-ATF-2; MGC20410; SARI; suppressor of AP-1 regulated by IFN

Molecular Weight

Mass (kDA):
29.703 kDA

Genomic Context

Mouse
Location:	19|19 A
Sequence:	19;

Diseases

• Neoplasm Metastasis
• Malignant Neoplasms
• Carcinoma
• Adenocarcinoma
• Fibrosarcoma
• Metastatic Malignant Neoplasm To The Lymph Node
• Neoplasms
• Liver Carcinoma

• Liver Neoplasms
• Malignant Paraganglionic Neoplasm
• Adenocarcinoma Of Lung (disorder)

Pathways

• Cell Development

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/Batf2

Three Best Uses of the BATF2 Marker From Boster Bio

Boster Bio has a new marker that may be perfect for scientists. Scientists can submit results to applications, species, or special samples using the BATF2 marker. Boster also offers product credit for scientists. This credit is available to scientists all over the world. Read on to find out more. Don't forget sharing your research! Here are three great applications of the BATF2 biological marker.

Primary antibodies of high affinity

The identification of antigens is a significant challenge in the development of high-affinity primaries antibodies. To make a specific antigen, the antigen must first be exposed to it. Because of the antibody's high affinity, this may not be possible in all cases. Also, the elution procedure might require harsher methods, such as denaturing. The BATF2 marker is one method to identify antigens within a sample.

First, the InsA(4) marker determined the high affinity for PR-IgM. Then, peptide-ratio ELISA was performed to determine the affinity of IgM to the insulin peptide. Streptavidin was coated plates with InsA(4) binding sites for this purpose. The repeated-measure ANOVA test was used to calculate the statistical significance of the results. The mice were then used to test for diabetes.

It is interesting to note that high-affinity primary antibody using the BATF2-marker can also be made from a variety of mouse strains. GANP(r) mice, for example, have a genetic background that allows for mutations. The results from these mice demonstrate that the antibodies produced from these strains are more diverse than those from wild-type mice. This is consistent with previous studies using FCMR-deficient mice, which have increased plasma cell differentiation and autoantibody production.

BCRs of IgD-class BCRs play an important role in the regulation of antibody secretion from B cells. They regulate the expression and secretion IgM antibody by controlling the expression CXCR4 on the B cells. It is possible that IgD-deficient cells have a lower threshold for activation, and secretion of IgM antibody. Further research is needed to determine if IgD deficient B cells have decreased sensitivity for IgD-containing antibodies.

DNA methyltransferase inhibitors

Boster Bio DNA methyltransferases inhibitors block DNMT1's activity. They are able to inhibit DNMT1 & DNMT3, the genes that are required for DNA methyl chains formation. These genes are found in many tumors and have been shown to suppress the immune system. Boster Bio has shown that DNMT inhibitors can block ERVs.

These molecules covalently attach a methyl atom to cytosine. This inhibits DNA methylation, resulting in 5-methylcytosine. They covalently trap DNMTs within the DNA, blocking their action. High-dose DNMT inhibitors can prevent DNA replication and cause tumor cells death. These molecules may have side effects. These drugs can cause hepatotoxicity if taken in high amounts.

Decitabine increased PTEN and PPP2R2B gene expression. Moreover, it inhibited PDK1 and activated AKT/mTOR pathways. It also decreased the interaction between PP2A et P70. BEZ235 resistance might be reversed if methyltransferases are inhibited. BEZ235 resistance may be reduced by inhibiting DNAmethyltransferases.

DNMT inhibitions are more effective when they are combined with anti-tumor medicines. However, there are still many trials to be done before this treatment can spread widely. The sample size for clinical trial is currently small. Most studies involve less than 50 patients. Few clinical trials are randomized. Only a few clinical trials are designed in blinded controlled, randomized trials.

Zebularine

The BATF2 genes regulate the growth of tumor cell. Cancer progression can be caused by aberrant Cytosine methylation. Inhibitors of DNA methyltransferases like zebularine can reactivate silenced genes and stop their growth. Both zebularine and boster bio have different interactions with BATF2.

Zebularine inhibits tumor cell proliferation and increases apoptosis. It lowers levels of Bcl-2 and cyclin A.

Infiltrations of immune cells in SA Patients

CIBERSORT was used to determine infiltration of immune systems in SA patients. Serum samples from human research participants were used for confirmatory analyses. Patients with active pulmonary saemia were found to have high levels for the markers PDK4 & BATF2. This finding suggests that immune cells are associated with SA development.

BATF2 acts as a regulator of immunepathologies in tissues and is critical for the prevention of listeriosis. Blockade or omission of this gene can lead to Type-1 and Type-2 disease. It is therefore important to exercise caution when attempting to modulate Type-2 diseases with strategies based on BATF2 blockade.

Researchers discovered that mice lacking BATF2 had higher levels of profibrotic cytokines in comparison to mice with intact BATF2. Batf2-/ mice did not show any decrease in the infiltration of these pro-fibrotic cytokines into SA patients. Batf2 can be found in both liver and splenic macrophages. BATF2 is also expressed by immune cells in patients with a variety of infections, such as influenza, rhinovirus infection, and even sarcoidosis.

The BATC2 marker can be used to detect the infiltration of immune cells by SA patients. BATF2 can be used as a biomarker to confirm diagnosis and is useful for detecting SA in patients. It has been proven to be crucial for controlling small intestine inflammatory responses by T helper. However, the absence BATF2 could exacerbate the disease or lead to premature death.

BATF2 expression in SA cells could indicate an aggressive tumor. However, immunohistochemistry can also be used to detect infiltrating immune cell. Immunohistochemistry was used to evaluate the infiltration rate of immune cells in SA patients using Image Plus software. Infiltrated immune cells were associated with lower survival in group A than in group B. The results of this study, though not conclusive are encouraging.